Hengrui Therapeutics, Inc.

Revolution Medicines has strengthened its chances of becoming a leader in KRAS-targeting drugs with new Phase I results from zoldonrasib in non-small cell lung cancer (NSCLC). Analysts think the new m

Despite the ongoing upheaval across the agency, the US Food and Drug Administration maintained its typical reliability when it came to meeting user fee goal dates in the first quarter of 2025, the Pi

One of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel show

A string of complete response letters from the US FDA clouded the 2024 outlook for novel cancer therapies, but a productive pipeline is carrying enough candidates towards second half user fee goal dat